中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
19期
2942-2944
,共3页
胰腺炎%乌司他丁%地芬诺酯
胰腺炎%烏司他丁%地芬諾酯
이선염%오사타정%지분낙지
Pancreatitis%Ulinastatin%Diphenoxylate
目的 探讨乌司他丁联合地芬诺酯治疗重症急性胰腺炎的临床效果.方法 90例急性重症胰腺炎患者按数字表法随机分为观察组和对照组各45例,对照组采用乌司他丁进行治疗,观察组患者采用乌司他丁联合地芬诺酯辅助治疗,并在接受治疗前后进行肿瘤坏死因子-α、白细胞介素-6、白细胞介素-18的检测,并对患者的治疗疗效进行评价.结果 两组腹痛缓解时间、体征减轻时间、白细胞计数恢复时间、血淀粉酶恢复正常时间、尿淀粉酶恢复时间、平均住院时间分别为(4.3±1.4)d比(6.4±2.3)d、(4.1±1.5)d比(6.5±1.4)d、(7.3±3.5)d比(10.3±2.3)d、(4.5±1.5)d比(7.9±2.3)d、(5.4±1.2)d比(8.2±2.3)d、(22.3±3.7)d比(31.5±3.4)d,差异均有统计学意义(t=5.2319、7.8465、4.8052、8.3061、7.2403、12.2818,均P＜0.05)；两组患者在接受治疗后第3天、7天、14天的肿瘤坏死因子-α、白细胞介素-6、白细胞介素-18、内毒素等水平差异均有统计学意义(t=6.3843、8.9328、5.938、4.9381,均P＜0.05)；观察组治疗有效率为97.78％,明显高于对照组的88.89％ (x2=12.932,P＜0.05).结论 乌司他丁联合地芬诺酯治疗急性重症胰腺炎具有良好临床疗效.
目的 探討烏司他丁聯閤地芬諾酯治療重癥急性胰腺炎的臨床效果.方法 90例急性重癥胰腺炎患者按數字錶法隨機分為觀察組和對照組各45例,對照組採用烏司他丁進行治療,觀察組患者採用烏司他丁聯閤地芬諾酯輔助治療,併在接受治療前後進行腫瘤壞死因子-α、白細胞介素-6、白細胞介素-18的檢測,併對患者的治療療效進行評價.結果 兩組腹痛緩解時間、體徵減輕時間、白細胞計數恢複時間、血澱粉酶恢複正常時間、尿澱粉酶恢複時間、平均住院時間分彆為(4.3±1.4)d比(6.4±2.3)d、(4.1±1.5)d比(6.5±1.4)d、(7.3±3.5)d比(10.3±2.3)d、(4.5±1.5)d比(7.9±2.3)d、(5.4±1.2)d比(8.2±2.3)d、(22.3±3.7)d比(31.5±3.4)d,差異均有統計學意義(t=5.2319、7.8465、4.8052、8.3061、7.2403、12.2818,均P＜0.05)；兩組患者在接受治療後第3天、7天、14天的腫瘤壞死因子-α、白細胞介素-6、白細胞介素-18、內毒素等水平差異均有統計學意義(t=6.3843、8.9328、5.938、4.9381,均P＜0.05)；觀察組治療有效率為97.78％,明顯高于對照組的88.89％ (x2=12.932,P＜0.05).結論 烏司他丁聯閤地芬諾酯治療急性重癥胰腺炎具有良好臨床療效.
목적 탐토오사타정연합지분낙지치료중증급성이선염적림상효과.방법 90례급성중증이선염환자안수자표법수궤분위관찰조화대조조각45례,대조조채용오사타정진행치료,관찰조환자채용오사타정연합지분낙지보조치료,병재접수치료전후진행종류배사인자-α、백세포개소-6、백세포개소-18적검측,병대환자적치료료효진행평개.결과 량조복통완해시간、체정감경시간、백세포계수회복시간、혈정분매회복정상시간、뇨정분매회복시간、평균주원시간분별위(4.3±1.4)d비(6.4±2.3)d、(4.1±1.5)d비(6.5±1.4)d、(7.3±3.5)d비(10.3±2.3)d、(4.5±1.5)d비(7.9±2.3)d、(5.4±1.2)d비(8.2±2.3)d、(22.3±3.7)d비(31.5±3.4)d,차이균유통계학의의(t=5.2319、7.8465、4.8052、8.3061、7.2403、12.2818,균P＜0.05)；량조환자재접수치료후제3천、7천、14천적종류배사인자-α、백세포개소-6、백세포개소-18、내독소등수평차이균유통계학의의(t=6.3843、8.9328、5.938、4.9381,균P＜0.05)；관찰조치료유효솔위97.78％,명현고우대조조적88.89％ (x2=12.932,P＜0.05).결론 오사타정연합지분낙지치료급성중증이선염구유량호림상료효.
Objective To investigate ulinastatin combined with diphenoxylate efficacy patients with severe acute pancreatitis.Methods 90 cases with severe acute pancreatitis patients hospital as the object of study,were randomly divided into experimental group and control group,ulinastatin replication treatment control group,the experimental group were treated with ulinastatin joint diphenoxylate adjuvant treatment,and before and after the medical treatment of TNF-α,IL-6,IL-18 the detection,and the treatment efficacy of the patient's evaluation.Results The patients abdominal pain time,signs alleviate time,the white blood cell count recovery time to resume normal serum amylase time,the urine amylase recovery time,average length of stay (4.3 ± 1.4)d vs (6.4 ± 2.3)d,(4.1 ± 1.5)d vs (6.5 ±1.4)d,(7.3 ±3.5)d vs (10.3 ±2.3)d,(4.5 ±l.5)d vs (7.9 ±2.3)d,(5.4±l.2)d vs (8.2 ±2.3)d,(22.3 ±3.7)d vs (31.5 ±3.4)d(t =5.2319,7.846,5,4.8052,8.3061,7.2403,12.2818,all P ＜0.05),the two groups of patients receiving treatment,3d,7d,and 14d of TNF-α,IL-6,IL-18,the levels of endotoxin has statistical difference (P ＜ 0.05) (t =6.3843,8.9328,5.938,4.9381,all P ＜ 0.05),the experimental group patients with an effective rate of 97.78％,88.89％ was significantly better than the control group(x2 =12.932,P ＜ 0.05).Concltusion Ulinastatin combined with diphenoxylate has good clinical efficacy in acute severe pancreatitis,which is worthy of promotion in the clinical.
